成人Evans综合征:全国队列的发病率、患病率与生存分析
丹麦1977-2017年全国回顾性队列纳入242例Evans综合征患者,并与年龄性别匹配的单纯免疫性血小板减少症、单纯自身免疫性溶血性贫血及一般人群队列比较。年发病率和患病率显著上升,2016年分别达1.8/百万人年和21.3/百万人。中位生存7.2年(原发10.9年,继发1.7年),继发者5年生存38%。
要点
- Evans综合征年发病率和患病率在研究期间显著上升,2016年分别为1.8/百万人年和21.3/百万人。
- 中位生存7.2年,原发Evans综合征10.9年,继发Evans综合征1.7年。
- 继发Evans综合征5年生存38%,死亡率高于其他队列,主要死因为出血、感染和血液系统恶性肿瘤。
核心结论
- 原发性和继发性Evans综合征均预后不良。
- 致死性并发症可能主要源于潜在自身免疫性溶血性贫血和免疫性血小板减少症的表现。
- 研究结果提示,怀疑Evans综合征应进行警惕的临床随访。
研究设计与样本
- 全国性回顾性研究,链接丹麦健康登记系统识别1977-2017年242例Evans综合征患者。
- 设置三个年龄和性别匹配的对照队列:单纯免疫性血小板减少症、单纯自身免疫性溶血性贫血及一般人群队列。
主要发现
- Evans综合征队列诊断时平均年龄58.5岁,女性占51.2%,27.3%分类为继发性Evans综合征。
- 研究期间年发病率和患病率显著上升,2016年分别达1.8/百万人年和21.3/百万人。
- 中位生存7.2年:原发性Evans综合征10.9年,继发性Evans综合征1.7年。
- 继发性Evans综合征死亡率高于其他所有队列,5年生存率38%。
- Evans综合征患者主要死因为出血、感染和血液系统恶性肿瘤。
关键数值与推荐
- 2016年Evans综合征年发病率1.8/百万人年,患病率21.3/百万人。
- 继发性Evans综合征5年生存率38%。
临床怎么用
- 怀疑Evans综合征时应进行警惕的临床随访。
- 需要国际协作以推进对这一罕见疾病最佳管理的认识。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with Evans syndrome have both immune thrombocytopenia and autoimmune hemolytic anemia, but little is known about the epidemiology of this rare syndrome. Evans syndrome can be primary or secondary. This nationwide retrospective study linked health registries to identify 242 patients with Evans syndrome in Denmark in 1977-2017. For comparison, we identified three age-matched and sex-matched cohorts of patients with only immune thrombocytopenia or only autoimmune hemolytic anemia, and a general population cohort. The Evans syndrome cohort had a mean age of 58.5 years at diagnosis, 51.2% were women, and 27.3% were classified as secondary Evans syndrome. The annual Evans syndrome incidence and prevalence rose significantly during the study period, to 1.8 per million person-years and 21.3 per million persons, respectively, in 2016. The median survival with Evans syndrome was 7.2 years (primary Evans syndrome: 10.9 years; secondary Evans syndrome: 1.7 years). Secondary Evans syndrome was associated with higher mortality rates than any of the other cohorts, with a 5-year survival of 38%. Among patients with Evans syndrome, the prevailing causes of death were bleeding, infections, and hematological cancer. In conclusion, we found that both primary and secondary Evans syndrome conferred a poor prognosis. Lethal complications probably derive primarily from manifestations of underlying autoimmune hemolytic anemia and immune thrombocytopenia. Our findings suggested that suspicion of Evans syndrome should prompt vigilant clinical follow-up. International collaborations are warranted to advance our knowledge of optimal management of this rare disease.
引用
- Hansen DL, Möller S, Andersen K, et al. Evans syndrome in adults - incidence, prevalence, and survival in a nationwide cohort. Am J Hematol. 2019. PMID: 31292991. doi:10.1002/ajh.25574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。